BiotechTube
Home/Nanopharmaceutics/James D. Talton, Ph.D.
JD

James D. Talton, Ph.D.

President & CEO (of parent TRON Group Inc. and subsidiaries)

Nanopharmaceutics

Roles

President & CEO (of parent TRON Group Inc. and subsidiaries)atNanopharmaceutics
President and CEOatAlchem Laboratories

Therapeutic Areas

OncologyCentral Nervous System (CNS) DisordersDiabetesInfectious Diseases

Nanopharmaceutics Pipeline

DrugIndicationPhase
Triapine®CancerClinical
Ammonium TetrathiomolybdateCancerClinical
Aza-TdCCancerClinical
NanoBUP™CNS DisordersClinical
PRX-3140CNS DisordersClinical
NP-18-2CNS DisordersClinical
NP-18-3CNS DisordersClinical
Ramoplanin™Infectious DiseasesClinical

Leadership Team at Nanopharmaceutics

JT
Judy Talton, MS, ARNP
Chief Clinical Officer & acting Chief Financial Officer
View full Nanopharmaceutics profile